Evidence map›Paper›PMID 42597410›Full record

ArticleFrontiers in oncology2026

Real-world uptake of neoadjuvant chemoimmunotherapy and surgery in patients with stage II-IIIB non-small cell lung cancer.

Claire Norman, Andrew Giles, Andrew Robinson, Mihaela Mates, Sofia Genta, Maitha Al Sibani, Luxiga Thanabalachandran, Daniel Jafari, Wilma Hopman, Yuchen Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Claire NormanQueen's School of Medicine, Kingston, ON, Canada.
Andrew GilesDepartment of Surgery, Division of Thoracic Surgery, Kingston, ON, Canada.
Andrew RobinsonCancer Centre of Southeastern Ontario, Kingston, ON, Canada.
Mihaela MatesCancer Centre of Southeastern Ontario, Kingston, ON, Canada.
Sofia GentaCancer Centre of Southeastern Ontario, Kingston, ON, Canada.
Maitha Al SibaniDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Luxiga ThanabalachandranQueen's School of Medicine, Kingston, ON, Canada.
Daniel JafariDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Wilma HopmanClinical Research Centre, Kingston Health Sciences Centre, Kingston, ON, Canada.
Yuchen LiCancer Centre of Southeastern Ontario, Kingston, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate real-world uptake, feasibility, and outcomes of neoadjuvant chemoimmunotherapy and surgery among patients with stage II-IIIB non-small cell lung cancer (NSCLC). Methods: This retrospective cohort study included all patients diagnosed with stage II-IIIB (AJCC 8th edition, excluding N3) NSCLC between August 2022 and August 2024 at the Cancer Centre of Southeastern Ontario (CCSEO). Data on patient characteristics, treatment uptake, surgical outcomes, pathological response, and survival were collected from electronic health records. Results: Of 587 patients diagnosed with NSCLC during the study period, 132 (22.5%) had stage II-IIIB disease and were included. Thirty-four patients (25.8%) underwent surgical resection, including 10 (29.4%) with upfront surgery and 24 (70.6%) following neoadjuvant chemoimmunotherapy. Overall, 26 patients (19.7%) initiated neoadjuvant chemoimmunotherapy 24/26 (92.3%) completed the planned regimen and proceeded to surgery. Among those undergoing surgery after neoadjuvant chemoimmunotherapy, pathological complete response and major pathological response were observed in 25% and 58.3% of patients, respectively. In exploratory analyses, neoadjuvant chemoimmunotherapy followed by surgery was associated with improved overall survival compared with not receiving this approach (log-rank p=0.009). Conclusion: In this real-world cohort, fewer than one in five patients with stage II-IIIB NSCLC received neoadjuvant chemoimmunotherapy, highlighting persistent barriers and need for alternative strategies. For those who did receive neoadjuvant chemoimmunotherapy, rates of treatment completion and surgery were higher than those reported in clinical trials..

Indexed as

chemotherapyimmunotherapyneoadjuvant chemoimmunotherapynon-small cell lung cancerperioperative therapyreal-world evidencesurgery

Identifiers

PMID42597410
PMCPMC13467973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.